-
28 April 2025
-
28 April 2025
Health Canada approves IQIRVO® as a first-in-class dual-peroxisome proliferator-activated receptor treatment for primary biliary cholangitis
IQIRVO® (elafibranor) is the first new medicine approved in nearly a decade for the treatment of rare cholestatic liver disease Primary Biliary Cholangitis...
-
04 May 2022
-
04 May 2022
Health Canada approves Ipsen’s CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory or Ineligible Differentiated Thyroid Cancer
Pivotal phase III trial data showed CABOMETYX® demonstrated a significant improvement in progression-free survival.1...
-
04 May 2022
-
04 May 2022
Santé Canada approuve le CABOMETYX® d’Ipsen pour les patients atteints d’un cancer de la thyroïde différencié réfractaire ou inadmissibles à l’iode radioactif ayant déjà été traités
Les données de l’étude pivot de phase III montrent que CABOMETYX® apporte une amélioration notable dans la survie sans progression1....
-
28 April 2025
-
28 April 2025
Santé Canada approuve IQIRVO® comme traitement innovant par activation double des récepteurs pour stimuler la prolifération des peroxysomes dans la cholangite biliaire primitive
IQIRVO® (elafibranor) est le premier nouveau médicament approuvé depuis près de dix ans pour le traitement d'une maladie hépatique rare appelée cholangite biliaire primitive....
-
20 October 2021
-
20 October 2021
Health Canada approves Ipsen’s CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for adults with advanced or metastatic renal cell carcinoma
Pivotal phase III trial data showed CABOMETYX® in combination with OPDIVO® demonstrated superior efficacy compared to sunitinib across all key endpoints, reducing the risk of death by 40 per cent,1 giving Canadians living with kidney cance...
-
04 May 2020
-
04 May 2020
Ipsen enters into an option agreement with IRICoR and Université de Montréal for a discovery-stage oncology program
PARIS, France, and MONTREAL, Canada, 04 May 2020 — Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Université de Montréal...
-
16 March 2021
-
16 March 2021
Health Canada Approves INCRELEX®, First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents
Mississauga, ON, March 16, 2021 – Ipsen Biopharmaceuticals Canada Inc. today announced the commercial availability of INCRELEX® (mecasermin) for the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed seve...
-
20 October 2021
-
20 October 2021
Santé Canada approuve le CABOMETYX® (cabozantinib) d’Ipsen en association avec OPDIVO® (nivolumab) comme traitement de première ligne pour les adultes atteints d’adénocarcinome rénal avancé ou métastatique
Les données de l’étude pivot de phase III ont montré que CABOMETYX® en association avec OPDIVO® présente une efficacité supérieure au sunitinib pour tous les critères d’évaluation clés, en réduisant le risque de décès de 40...
-
07 January 2020
-
07 January 2020
Ipsen Announces the Availability of the Newly Designed Delivery System for Somatuline® Autogel® (lanreotide injection)
Mississauga, ON – January 7, 2020 – Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for Somatuline® Autogel® (lanreotide injection) 60, 90, and 120 mg. The new pre-filled syringe is ...
-
12 November 2019
-
12 November 2019
Health Canada approves CABOMETYXTM (cabozantinib) Giving Physicians and Adult Patients a New Second-Line Option in the Fight Against Advanced Hepatocellular Carcinoma
CABOMETYX™ slows disease progression and improves survival for patients with advanced liver canceri previously treated with sorafenibii...